Cantor Reiterates Buy on TrovaGene Inc Following Data Presentations
In a research report issued today, Cantor analyst Sung Ji Nam reiterated a Buy rating on TrovaGene Inc (NASDAQ:TROV) with an $8 price target, after several presentations at major medical conferences.
Nam noted, “TROV has underway clinical studies with 15 leading cancer treatment centers around the world (>2,500 patients in aggregate) involving its liquid biopsy platform (PCM). TROV’s initial target cancer areas are lung, colorectal, pancreatic, and melanoma. For example, TROV has underway four clinical studies for lung cancer, and expects to enroll over 500 patients in aggregate. TROV expects to present and publish results from these studies throughout this year to drive early adoption for PCM starting in 2H.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Sung Ji Nam has a total average return of 13.7% and a 83.3% success rate. Nam has a -50.2% average return when recommending TROV, and is ranked #581 out of 3516 analysts.